guest ::
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
In
Haematologica : journal of the European Hematology Association 109(6), Seiten/Artikel-Nr.:1973-1976
2024
Online
DOI: 10.3324/haematol.2023.284346
DOI: 10.18154/RWTH-CONV-254030
URL: https://publications.rwth-aachen.de/record/1007647/files/1007647.pdf
Einrichtungen
OpenAccess: 
PDF
Dokumenttyp
Journal Article
Format
online, print
Sprache
English
Anmerkung
Peer reviewed article
Externe Identnummern
SCOPUS: SCOPUS:2-s2.0-85195226669
WOS Core Collection: WOS:001250402000043
PubMed: pmid:38385304
Interne Identnummern
RWTH-CONV-254030
Datensatz-ID: 1007647
Beteiligte Länder
France, Germany
; 
; 
; 
; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
PDF